New combination therapy for people with advanced KRAS G12C lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called HS-10370 combined with other anti-cancer treatments for people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if this combination can shrink or control tumors better than other options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have advanced lung cancer (NSCLC) that has spread and is not curable by surgery or radiation
- Your tumor has a specific change called the KRAS G12C mutation
- You have not received any prior treatment for advanced cancer
- You are in relatively good health and able to take care of yourself (ECOG 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HS-10370 given along with other anticancer treatments for advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if this combination is safe and effective for people who have run out of standard options.
This trial tests two new targeted drugs (IN10018 and D-1553) together as a first treatment for advanced non-squamous lung cancer with a specific KRAS G12C mutation. It compares this combination to standard therapy to see if it works better.
This trial tests a new combination of two targeted medicines for advanced non-small cell lung cancer with a specific gene change (KRAS G12C). The goal is to see if this combination can shrink or slow the cancer.
This trial tests a new targeted pill (HS-10370) combined with standard chemotherapy, with or without an immunotherapy drug (adebrelimab), versus another standard treatment (tislelizumab plus chemotherapy) as the first treatment for advanced lung cancer with a KRAS G12C mutation. The goal is to see if the new combination works better and is safe.
This trial tests a combination of two targeted drugs (JAB-21822 and JAB-3312) compared to standard chemotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It is for people who have not yet received any cancer treatment for their advanced disease.
This trial tests a new drug called HS-10541, which may target a specific genetic change in your tumor (KRAS G12C mutation). The study aims to see if this drug is safe and effective, either alone or with other cancer treatments, for people with advanced cancer that hasn't responded to standard therapy.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.